Vaxcyte, Inc. Overview
Pro stress-test →Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The company leverages proprietary cell-free protein synthesis technology to develop next-generation pneumococcal conjugate vaccines and other bacterial disease vaccines addressing critical unmet medical needs.
Strategic Profile
Pro stress-test →VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company's system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits.
Competitive Landscape
Pro stress-test →Vaxcyte competes in the pneumococcal vaccine market against established players including Pfizer (Pneumovax 23), Merck (Pneumovax), and GSK, which market lower-valency PCV candidates. Vaxcyte's VAX-31 (31-valent) and VAX-24 (24-valent) candidates are designed to provide broader serotype coverage than current standard-of-care vaccines, targeting a multi-billion dollar market opportunity.
Industry Context
Vaxcyte, Inc. operates in Biopharmaceutical - Vaccine Development.
Key facts
Founded: 2013 · Headquarters: San Carlos, US · Market cap: $6.04B